RCEL Avita Medical, Inc. - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 6, 2026RCEL Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
RCEL Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 30 de junio de 2020 | 1-for-5 | Inversa |
Acerca de Avita Medical, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Avita Medical is a clinical and commercial company developing and marketing a range of regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage (temporization) after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts.
Company history
Originally named "Clinical Cell Culture" and listed on the ASX under the symbol "C3", the company restructured under the name "Avita Medical" in June 2008. In 2015, the company conducted a strategic divestment of its respiratory business, including the Breath-a-Tech and Funhaler products, to support focus on its regenerative products.
Avita Medical is traded both on the Australian stock market under the ticker symbol AVH and on the NASDAQ Capital Market under the ticker symbol RCEL.
ReCell, spray-on skin
ReCell is a device that enables clinicians to treat wounds and skin defects using very small samples of the patient's own cells. The procedure is performed on site at bedside and takes approximately 25 minutes to complete and does not require laboratory facilities, off-site culture of tissues or specialized staff. ReCell is approved in the United States, Europe, the United Kingdom, Australia, New Zealand, Japan and China.
February 12, 2018 AVITA Medical announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be treated in the United States with the ReCell Autologous Cell Harvesting Device under a FDA Compassionate Use Investigational Device Exemption (IDE) program. Under the expanded protocol, up to 88 patients with life-threatening injuries, including severe burns, may be treated with ReCell. This is the fifth expansion to the Compassionate Use protocol for ReCell approved by the FDA and expands by 20 the number of patients who may be treated. Eligible patients are those who have insufficient healthy skin available for standard skin grafting treatment of their injuries and whose treating physicians believe there to be no suitable alternative treatment.
In October 2017, Avita Medical started to raise a goal of $17 million in capital for the product. The company worked with the Biomedical Advanced Research and Development Authority (BARDA) to raise money toward commercializing the product on the U.S. market.
September 28, 2017 Avita Medical announced submission of U.S. FDA Premarket Approval (PMA) Application for the ReCell device for treatment of burn injuries. The PMA submission includes clinical data from the two U.S. randomized, controlled trials with combined enrollment of 131 patients at twelve leading burn centers across the United States. The later trial demonstrated over 30% reduction in donor skin harvesting while achieving comparable near-term healing and long-term scar outcomes for treatment of third-degree burn injuries. Results from the earlier trial demonstrate a 97.5% reduction in donor skin harvested for treatment of second-degree burn injuries. The submission also includes a review of 55 cases of compassionate use of ReCell for extensive burn injuries.
September 21, 2017 Avita Medical announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes funding for key clinical and health economics research in U.S. pediatric burn care and extends Avita's Project Bioshield contract through to September 2022. Avita Medical has had a strong relationship with BARDA since the execution of a five-year contract in September 2015. Under the base contract BARDA made an initial investment of US$16.9 million to support Avita's ongoing U.S. clinical regulatory program towards FDA Premarket Approval (PMA), and to procure 5,000-plus ReCell devices. The contract also allowed BARDA to exercise future options to support additional clinical trials, and provide surge capacity for up to another 20,000 ReCell devices. Supplemental funding worth up to US$7.96 million was also provided to Avita under the contract in June 2016, to provide further operational support to Avita's PMA preparation and Compassionate Use program.
On September 20, 2018, Avita Medical's ReCell wound care device received FDA PMA approval.
US Government grant
In 2009 the United States Armed Forces Institute of Regenerative Medicine provided Avita with a US$1.45 million grant to hasten the approval of the ReCell kit with the U.S. Food and Drug Administration.
Necrotizing fasciitis
In 2018 a burn center in Phoenix, Arizona held a press conference to discuss the ongoing results of using ReCell to treat a woman with flesh-eating bacteria also known as necrotizing fasciitis.
== References ==
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | RCEL | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | -8.9promedio 5A ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.2promedio 5A ≈4.6 | ≈4.6 | 44.3 | Infravalorado | |
| P/C (MRQ) | -14.1promedio 5A ≈19.4 | ≈19.4 | · | · | |
| EV / EBITDA (TTM) | -13.1promedio 5A ≈-5.6 | ≈-5.6 | · | · | |
| Precio / FCF (TTM) | -16.0promedio 5A ≈-6.6 | ≈-6.6 | · | · | |
| Precio / Flujo de Caja (TTM) | -16.2promedio 5A ≈-7.1 | ≈-7.1 | · | · | |
| EV / Ingresos (TTM) | 5.7promedio 5A ≈4.4 | ≈4.4 | · | · | |
| EV / FCF (TTM) | -17.4promedio 5A ≈-5.9 | ≈-5.9 | · | · | |
| Precio / Valor Contable Tangible (MRQ) | -11.9 | · | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | RCEL | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Bruto (TTM) | 81.6%promedio 5A ≈83.7% | ≈83.7% | · | · | |
| Margen Operativo (TTM) | -46.6%promedio 5A ≈-78.1% | ≈-78.1% | -283.6% | De primer nivel | |
| Margen EBITDA (TTM) | -43.3%promedio 5A ≈-76.1% | ≈-76.1% | -281.6% | De primer nivel | |
| Margen antes de impuestos (TTM) | -56.9%promedio 5A ≈-77.9% | ≈-77.9% | -286.2% | De primer nivel | |
| Margen de Beneficio Neto (TTM) | -57.0%promedio 5A ≈-78.0% | ≈-78.0% | -337.7% | De primer nivel | |
| ROA (TTM) | -81.4%promedio 5A ≈-48.7% | ≈-48.7% | -43.7% | Débil | |
| ROE (TTM) | 211.5%promedio 5A ≈-126.2% | ≈-126.2% | -37.3% | De primer nivel | |
| ROIC | -161.5%promedio 5A ≈-90.8% | ≈-90.8% | -70.9% | Débil |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | RCEL | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Deuda / Patrimonio (MRQ) | -1.7promedio 5A ≈2.5 | ≈2.5 | · | · | |
| Ratio corriente (MRQ) | 0.4promedio 5A ≈4.9 | ≈4.9 | 5.3 | Baja liquidez | |
| Ratio Rápido (MRQ) | 0.3promedio 5A ≈4.5 | ≈4.5 | 2.5 | Baja liquidez | |
| Long-Term Debt / Equity (Deuda a Largo Plazo / Patrimonio) | 0.0promedio 5A ≈3.4 | ≈3.4 | · | · | |
| Interest Coverage (Cobertura de Intereses) | -8.5promedio 5A ≈-443.9 | ≈-443.9 | · | · |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | RCEL | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | 11.5%promedio 5A ≈28.4% | ≈28.4% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | 27.7% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | RCEL | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 1.1promedio 5A ≈0.6 | ≈0.6 | 0.0 | De primer nivel | |
| Inventory Turnover (Rotación de Inventario) | 1.8promedio 5A ≈2.0 | ≈2.0 | · | · | |
| Receivables Turnover (Rotación de Cuentas por Cobrar) | 6.9promedio 5A ≈8.2 | ≈8.2 | · | · | |
| Revenue / Employee (Ingresos / Empleado) | ≈$316.9K | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 5, 2026 | $-0.25 | $-0.29 | 14.5% |
| 31 de marzo de 2026 | May 14, 2026 | $-0.35 | $-0.29 | -22.5% |
| 31 de diciembre de 2025 | $-0.38 | $-0.34 | -10.9% | |
| 30 de septiembre de 2025 | $-0.46 | $-0.29 | -58.8% | |
| 30 de junio de 2025 | $-0.38 | $-0.25 | -50.2% | |
| 31 de marzo de 2025 | $-0.53 | $-0.39 | -35.0% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72M | $64M | $50M | $34M | · | $14M | $5M | |
| Cost of Revenue | $13M | $9M | $8M | $6M | · | $3M | $1M | |
| Gross Profit | $59M | $55M | $42M | $28M | · | $11M | $4M | |
| R&D Expense | $21M | $20M | $21M | $14M | · | $9M | $8M | |
| SG&A Expense | $27M | $33M | $28M | $23M | · | $33M | $15M | |
| Operating Expenses | $101M | $112M | $86M | $59M | · | $58M | $36M | |
| Operating Income | $-43M | $-57M | $-43M | $-28M | · | $-43M | $-26M | |
| Interest Expense | $5M | $5M | $1M | $16.0K | · | $33.0K | $27.0K | |
| Other Non-op | $-1M | $163.0K | $8M | $892.0K | · | · | · | |
| Pretax Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| Income Tax | $11.0K | $54.0K | $66.0K | $36.0K | · | $4.0K | $-121.0K | |
| Net Income | $-49M | $-62M | $-35M | $-27M | · | $-42M | $-25M | |
| EPS (Basic) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| EPS (Diluted) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | $1.56 | |
| Shares (Basic) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| Shares (Diluted) | 27,860,784 | 25,883,056 | 25,331,264 | 25,000,180 | · | 20,290,966 | 16,064,588 | |
| EBITDA | $-40M | $-55M | $-42M | $-27M | · | · | · |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $14M | $22M | $18M | $56M | $74M | $20M | |
| Short-term Investments | $8M | $22M | $67M | $61M | $30M | · | · | |
| Receivables | $9M | $12M | $8M | $4M | $3M | $2M | $1M | |
| Inventory | $7M | $7M | $6M | $2M | $2M | $1M | $742.0K | |
| Prepaid Expense | $1M | $2M | $2M | $2M | $1M | $990.0K | $1M | |
| Other Current Assets | · | · | $18.0K | $127.0K | $15.0K | $75.0K | $125.0K | |
| Current Assets | $35M | $57M | $104M | $87M | $92M | $78M | $24M | |
| PP&E (Net) | $9M | $10M | $2M | $1M | $1M | $1M | $1M | |
| Accum. Depreciation | $5M | $3M | $2M | $2M | $2M | $881.0K | $667.0K | |
| Intangibles | $6M | $6M | $487.0K | $465.0K | $443.0K | $364.0K | $225.0K | |
| Other Non-current Assets | $612.0K | $546.0K | $355.0K | $122.0K | $638.0K | $1.0K | $125.0K | |
| Total Assets | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Accounts Payable | $9M | $6M | $4M | $3M | $3M | $4M | $2M | |
| Current Liabilities | $63M | $20M | $13M | $11M | $9M | $8M | $4M | |
| Capital Leases | $2M | $3M | $2M | $306.0K | $918.0K | $2M | · | |
| Other Non-current Liabilities | · | · | · | · | $113.0K | $0 | $42.0K | |
| Total Liabilities | $73M | $75M | $62M | $13M | $11M | $10M | $5M | |
| Long-term Debt | $43M | $42M | · | · | · | · | · | |
| Total Debt | $43M | $42M | $40M | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $394M | $368M | $350M | $340M | $332M | $259M | $165M | |
| Retained Earnings | $-408M | $-360M | $-298M | $-263M | $-236M | $-195M | $-153M | |
| AOCI | $-1M | $-2M | $-2M | $8M | $8M | $8M | $8M | |
| Stockholders' Equity | $-17M | $4M | $49M | $85M | $105M | $72M | $21M | |
| Liabilities + Equity | $56M | $80M | $112M | $98M | $116M | $82M | $26M | |
| Shares Outstanding | 30,571,662 | 26,354,042 | 25,682,078 | 25,208,436 | 24,925,743 | 21,467,912 | 18,712,996 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $1M | $632.0K | $568.0K | · | $465.0K | $269.0K | |
| Stock-based Comp | $10M | $13M | $8M | $7M | · | $16M | $2M | |
| Amort. of Intangibles | $600.0K | $93.0K | $35.0K | $58.0K | · | $119.0K | $0 | |
| Other Non-cash | $6M | $-2M | $-12M | $9.0K | · | · | · | |
| Operating Cash Flow | $-31M | $-49M | $-38M | $-19M | · | $-23M | $-19M | |
| CapEx | $1M | $9M | $1M | $452.0K | · | $590.0K | $1M | |
| Investing Cash Flow | $12M | $37M | $2M | $-19M | · | $-847.0K | $-1M | |
| Debt Issued | · | · | $39M | · | · | · | · | |
| Net Debt Issued | · | · | $39M | · | · | · | · | |
| Stock Issued | $15M | · | · | · | · | $82M | $32M | |
| Net Stock Activity | $15M | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $4M | $40M | $900.0K | · | $77M | $30M | |
| Net Change in Cash | $-4M | $-8M | $4M | $-38M | · | $53M | $9M | |
| Taxes Paid | $15.0K | $41.0K | $44.0K | $17.0K | · | · | · | |
| Free Cash Flow | $-32M | $-58M | $-39M | $-20M | · | · | · | |
| Levered FCF | $-37M | $-63M | $-41M | $-20M | · | · | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.1% | 85.9% | 84.5% | 82.5% | · | · | · | |
| Operating Margin | -59.4% | -88.1% | -85.1% | -79.9% | · | · | · | |
| Net Margin | -67.8% | -96.3% | -70.6% | -77.5% | · | · | · | |
| Pretax Margin | -67.8% | -96.2% | -70.4% | -77.4% | · | · | · | |
| EBITDA Margin | -56.1% | -86.3% | -83.8% | -78.3% | · | · | · | |
| ROA | -71.4% | -64.6% | -33.7% | -24.9% | · | · | · | |
| ROE | 328.9% | -739.5% | -63.2% | -30.9% | · | · | · | |
| ROIC | -161.5% | -121.2% | -48.1% | -32.5% | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | 2.8 | 7.9 | 8.2 | · | · | · | |
| Quick Ratio | 0.4 | 2.4 | 7.3 | 7.7 | · | · | · | |
| Debt / Equity | -2.6 | 9.4 | 0.8 | · | · | · | · | |
| LT Debt / Equity | 0.0 | 9.4 | 0.8 | · | · | · | · | |
| Interest Coverage | -8.5 | -10.6 | -37.3 | -1719.1 | · | · | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 0.7 | 0.5 | 0.3 | · | · | · | |
| Inventory Turnover | 1.8 | 1.4 | 2.0 | 2.8 | · | · | · | |
| Receivables Turnover | 6.9 | 6.6 | 9.0 | 10.4 | · | · | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.54 | $0.17 | $1.91 | $3.36 | · | · | · | |
| Revenue / Share | $2.57 | $2.48 | $1.98 | $1.38 | · | · | · | |
| Cash Flow / Share | $-1.12 | $-1.89 | $-1.50 | $-0.76 | · | · | · | |
| Cash / Share | $0.34 | $0.53 | $0.86 | $0.72 | · | · | · | |
| EPS (TTM) | $-1.74 | $-2.39 | $-1.40 | $1.07 | · | $2.07 | · |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.5% | 28.1% | 45.7% | · | · | · | · | |
| Revenue CAGR 3Y | 27.7% | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $72M | $64M | $50M | $34M | · | $14M | · | |
| Net Income TTM | $-49M | $-62M | $-35M | $-27M | · | $-42M | · | |
| Market Cap | $105M | $337M | $352M | $166M | · | · | · | |
| Enterprise Value | $130M | $344M | $303M | · | · | · | · | |
| P/E | -2.0 | -5.4 | -9.8 | 6.2 | · | 14.8 | · | |
| P/S | 1.5 | 5.3 | 7.0 | 4.8 | · | · | · | |
| P/B | -6.3 | 75.0 | 7.2 | 2.0 | · | · | · | |
| P / Tangible Book | · | · | 7.3 | 2.0 | · | 9.1 | · | |
| P / Cash Flow | -3.4 | -6.9 | -9.3 | -8.7 | · | · | · | |
| P / FCF | -3.3 | -5.8 | -8.9 | -8.5 | · | · | · | |
| EV / EBITDA | -3.2 | -6.2 | -7.2 | · | · | · | · | |
| EV / FCF | -4.0 | -5.9 | -7.7 | · | · | · | · | |
| EV / Revenue | 1.8 | 5.3 | 6.0 | · | · | · | · | |
| Earnings Yield | -50.4% | -18.7% | -10.2% | 16.2% | · | 6.8% | · |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22M | $19M | $18M | $17M | $18M | $19M | $18M | $20M | $15M | $11M | $14M | $14M | $12M | $11M | $9M | $9M | |
| Cost of Revenue | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | |
| Gross Profit | $18M | $16M | $14M | $14M | $15M | $16M | $16M | $16M | $13M | $10M | $12M | $12M | $10M | $9M | $8M | $8M | |
| R&D Expense | $5M | $6M | $6M | $4M | $5M | $6M | $5M | $5M | $5M | $5M | $7M | $4M | $5M | $5M | $3M | $4M | |
| SG&A Expense | $6M | $6M | $7M | $7M | $7M | $6M | $7M | $10M | $8M | $9M | $8M | $6M | $6M | $8M | $5M | $5M | |
| Operating Expenses | $25M | $25M | $25M | $23M | $26M | $28M | $26M | $30M | $29M | $27M | $25M | $21M | $21M | $19M | $15M | $14M | |
| Operating Income | $-7M | $-9M | $-10M | $-9M | $-11M | $-12M | $-10M | $-14M | $-16M | $-17M | $-12M | $-9M | $-11M | $-10M | $-6M | $-6M | |
| Interest Expense | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $10.0K | $7.0K | $4.0K | $-3.0K | $6.0K | |
| Other Non-op | $688.0K | $-395.0K | $20.0K | $-3M | $2M | $-791.0K | $-314.0K | $-1M | $2M | $-66.0K | $6M | $615.0K | $801.0K | $725.0K | · | · | |
| Pretax Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| Income Tax | $33.0K | $-11.0K | $-16.0K | $15.0K | $4.0K | $8.0K | $19.0K | $-28.0K | $33.0K | $30.0K | $12.0K | $11.0K | $13.0K | $30.0K | $24.0K | $4.0K | |
| Net Income | $-8M | $-11M | $-12M | $-13M | $-10M | $-14M | $-12M | $-16M | $-15M | $-19M | $-7M | $-9M | $-10M | $-9M | $-5M | $-6M | |
| EPS (Basic) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| EPS (Diluted) | $-0.25 | $-0.35 | $-0.37 | $-0.46 | $-0.38 | $-0.53 | $-0.44 | $-0.62 | $-0.60 | $-0.73 | $-0.28 | $-0.34 | $-0.41 | $-0.37 | $0.22 | $0.22 | |
| Shares (Basic) | 30,749,894 | 30,540,872 | · | 28,393,445 | 26,367,548 | 26,253,565 | · | 25,983,929 | 25,760,278 | 25,637,783 | · | 25,401,754 | 25,239,723 | 25,202,088 | · | 25,006,995 | |
| Shares (Diluted) | 30,749,894 | 30,540,872 | · | 28,393,445 | 26,367,548 | 26,253,565 | · | 25,983,929 | 25,760,278 | 25,637,783 | · | 25,401,754 | 25,239,723 | 25,202,088 | · | 25,006,995 | |
| EBITDA | $-7M | $-8M | · | $-9M | $-11M | $-11M | · | $-14M | $-16M | $-17M | · | $-9M | $-11M | $-10M | · | $-6M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $8M | $10M | $15M | $12M | $15M | $14M | $19M | $17M | $17M | $22M | $51M | $37M | $28M | $18M | $24M | |
| Short-term Investments | $2M | $6M | $8M | $8M | $3M | $11M | $22M | $26M | $37M | $51M | $67M | $9M | $29M | $45M | $61M | $61M | |
| Receivables | $10M | $10M | $9M | $9M | $11M | $12M | $12M | $10M | $9M | $7M | $8M | $6M | $6M | $5M | $4M | $4M | |
| Inventory | $5M | $6M | $7M | $7M | $8M | $8M | $7M | $6M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $3M | $2M | $1M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | $8.0K | $135.0K | · | $26.0K | $525.0K | $29.0K | $127.0K | $17.0K | |
| Current Assets | $28M | $32M | $35M | $41M | $36M | $48M | $57M | $64M | $73M | $86M | $104M | $74M | $77M | $83M | $87M | $92M | |
| PP&E (Net) | $8M | $8M | $9M | $10M | $10M | $10M | $10M | $9M | $7M | $4M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Accum. Depreciation | $6M | $6M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Intangibles | $5M | $5M | $6M | $5M | $5M | $5M | $6M | $590.0K | $545.0K | $542.0K | $487.0K | $459.0K | $456.0K | $461.0K | $465.0K | $449.0K | |
| Other Non-current Assets | $593.0K | $534.0K | $612.0K | $1M | $839.0K | $287.0K | $546.0K | $546.0K | $473.0K | $401.0K | $355.0K | $236.0K | $285.0K | $230.0K | $122.0K | $548.0K | |
| Total Assets | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Accounts Payable | $6M | $7M | $9M | $8M | $7M | $9M | $6M | $4M | $4M | $4M | $4M | $3M | $4M | $4M | $3M | $3M | |
| Current Liabilities | $69M | $67M | $63M | $62M | $63M | $23M | $20M | $17M | $14M | $12M | $13M | $12M | $14M | $11M | $11M | $10M | |
| Capital Leases | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | $1M | $306.0K | $405.0K | |
| Total Liabilities | $76M | $75M | $73M | $70M | $71M | $74M | $75M | $69M | $64M | $64M | $62M | $17M | $16M | $14M | $13M | $12M | |
| Long-term Debt | · | · | $43M | $42M | · | · | $42M | · | · | · | · | · | · | · | · | · | |
| Total Debt | $47M | $46M | · | $42M | $42M | $41M | · | $43M | $41M | $41M | · | · | · | · | · | · | |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $400M | $396M | $394M | $393M | $374M | $371M | $368M | $364M | $359M | $353M | $350M | $347M | $344M | $342M | $340M | $338M | |
| Retained Earnings | $-427M | $-419M | $-408M | $-397M | $-384M | $-374M | $-360M | $-348M | $-332M | $-317M | $-298M | $-291M | $-282M | $-272M | $-263M | $-257M | |
| AOCI | $-82.0K | $648.0K | $-1M | $-1M | $-2M | $-413.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $8M | $8M | $8M | $8M | $7M | |
| Stockholders' Equity | $-28M | $-23M | $-17M | $-7M | $-13M | $-5M | $4M | $12M | $24M | $33M | $49M | $63M | $69M | $78M | $85M | $88M | |
| Liabilities + Equity | $48M | $52M | $56M | $64M | $58M | $70M | $80M | $81M | $88M | $97M | $112M | $81M | $86M | $93M | $98M | $100M | |
| Shares Outstanding | 30,926,847 | 30,776,689 | 30,571,662 | 30,493,111 | 26,613,678 | 26,434,658 | 26,354,042 | 26,217,629 | 25,949,906 | 25,789,051 | 25,682,078 | 25,550,694 | 25,447,615 | 25,327,761 | 25,208,436 | 25,030,902 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $605.0K | $627.0K | $700.0K | $574.0K | $552.0K | $521.0K | $409.0K | $310.0K | $204.0K | $203.0K | $187.0K | $164.0K | $146.0K | $135.0K | $130.0K | $138.0K | |
| Stock-based Comp | $2M | $1M | $1M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $2M | $2M | $1M | $3M | $1M | $1M | |
| Amort. of Intangibles | $196.0K | $204.0K | $160.0K | $153.0K | $152.0K | $135.0K | $36.0K | $23.0K | $17.0K | $17.0K | $9.0K | $9.0K | $8.0K | $9.0K | $8.0K | $8.0K | |
| Other Non-cash | · | $-1M | · | · | · | $335.0K | · | · | · | $-5M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-3M | $-10M | $-5M | $-5M | $-10M | $-10M | $-8M | $-7M | $-13M | $-21M | $-11M | $-9M | $-9M | $-9M | $-3M | $-3M | |
| CapEx | $108.0K | $19.0K | $-674.0K | $934.0K | $524.0K | $221.0K | $2M | $4M | $3M | $1M | $296.0K | $502.0K | $299.0K | $284.0K | $70.0K | $104.0K | |
| Investing Cash Flow | $4M | $2M | $11.0K | $-5M | $7M | $11M | $2M | $7M | $12M | $15M | $-57M | $22M | $18M | $19M | $-3M | $-8M | |
| Stock Issued | · | · | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $437.0K | $6M | $248.0K | $14M | $559.0K | $363.0K | $1M | $1M | $849.0K | $631.0K | $39M | $600.0K | $171.0K | $171.0K | $899.0K | $0 | |
| Net Change in Cash | $830.0K | $-2M | $-5M | $3M | $-3M | $820.0K | $-5M | $1M | $501.0K | $-5M | $-29M | $13M | $9M | $10M | $-6M | $-11M | |
| Taxes Paid | · | · | · | · | · | · | $20.0K | $2.0K | $19.0K | $17.0K | $0 | $0 | $44.0K | $9 | $0 | $0 | |
| Free Cash Flow | · | $-10M | · | · | · | $-11M | · | · | · | $-22M | · | · | · | $-9M | · | · | |
| Levered FCF | · | $-12M | · | · | · | $-12M | · | · | · | $-23M | · | · | · | $-9M | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 81.7% | · | 81.3% | 81.2% | 84.7% | · | 83.7% | 86.1% | 86.4% | · | 84.5% | 81.2% | 84.2% | · | 83.2% | |
| Operating Margin | -31.6% | -45.7% | · | -53.6% | -60.5% | -63.9% | · | -70.6% | -102.8% | -155.0% | · | -68.2% | -95.0% | -93.9% | · | -63.2% | |
| Net Margin | -35.3% | -55.1% | · | -77.3% | -53.9% | -74.9% | · | -82.9% | -101.3% | -168.0% | · | -63.8% | -88.3% | -87.4% | · | -61.5% | |
| Pretax Margin | -35.2% | -55.2% | · | -77.2% | -53.8% | -74.8% | · | -83.0% | -101.1% | -167.8% | · | -63.8% | -88.2% | -87.1% | · | -61.4% | |
| EBITDA Margin | -31.6% | -42.5% | · | -53.6% | -60.5% | -61.1% | · | -70.6% | -102.8% | -153.1% | · | -68.2% | -95.0% | -92.7% | · | -63.2% | |
| ROA | -14.5% | -17.5% | · | -18.2% | -13.6% | -16.6% | · | -20.0% | -17.7% | -19.6% | · | -9.6% | -11.0% | -9.3% | · | -4.9% | |
| ROE | 37.6% | 76.5% | · | -474.3% | -180.0% | -99.0% | · | -43.1% | -33.3% | -33.9% | · | -11.5% | -12.9% | -10.5% | · | -5.4% | |
| ROIC | -36.6% | -38.3% | · | -25.6% | -38.0% | -32.1% | · | -25.2% | -24.1% | -23.3% | · | -14.8% | -16.3% | -12.8% | · | -6.5% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.5 | · | 0.7 | 0.6 | 2.1 | · | 3.7 | 5.3 | 7.2 | · | 6.2 | 5.6 | 7.2 | · | 9.6 | |
| Quick Ratio | 0.3 | 0.4 | · | 0.5 | 0.4 | 1.6 | · | 3.2 | 4.6 | 6.3 | · | 5.6 | 5.2 | 6.8 | · | 9.2 | |
| Debt / Equity | -1.7 | -2.0 | · | -6.4 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| LT Debt / Equity | · | · | · | 0.0 | -3.3 | -9.1 | · | 3.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| Interest Coverage | -4.7 | -6.2 | · | -7.2 | -8.9 | -9.6 | · | -10.2 | -11.6 | -12.7 | · | -930.6 | -1595.0 | -2477.8 | · | -958.0 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.2 | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.6 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.9 | 0.7 | · | 0.8 | |
| Receivables Turnover | 2.0 | 1.8 | · | 1.8 | 1.8 | 1.9 | · | 2.4 | 2.1 | 1.9 | · | 2.9 | 2.4 | 2.6 | · | 3.1 |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.90 | $-0.75 | · | $-0.22 | $-0.48 | $-0.17 | · | $0.47 | $0.92 | $1.26 | · | $2.46 | $2.70 | $3.06 | · | $3.52 | |
| Revenue / Share | $0.71 | $0.63 | · | $0.60 | $0.70 | $0.71 | · | $0.75 | $0.59 | $0.43 | · | $0.54 | $0.47 | $0.42 | · | $0.36 | |
| Cash Flow / Share | · | $-0.33 | · | · | · | $-0.39 | · | · | · | $-0.81 | · | · | · | $-0.36 | · | · | |
| Cash / Share | $0.30 | $0.27 | · | $0.51 | $0.46 | $0.56 | · | $0.71 | $0.67 | $0.66 | · | $1.99 | $1.47 | $1.11 | · | $0.94 | |
| EPS (TTM) | $-1.43 | $-1.56 | · | $-1.81 | $-1.97 | $-2.19 | · | $-2.23 | $-1.95 | $-1.76 | · | $-0.90 | $-0.34 | $0.32 | · | · |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $76M | $72M | · | $72M | $75M | $72M | · | $60M | $54M | $51M | · | $45M | $41M | $37M | · | · | |
| Net Income TTM | $-43M | $-45M | · | $-49M | $-52M | $-57M | · | $-57M | $-50M | $-45M | · | $-34M | $-31M | $-26M | · | · | |
| Market Cap | $128M | $114M | · | $156M | $141M | $215M | · | $281M | $206M | $413M | · | $373M | $433M | $354M | · | $132M | |
| Enterprise Value | $163M | $146M | · | $175M | $167M | $231M | · | $279M | $192M | $387M | · | · | · | · | · | · | |
| P/E | -2.9 | -2.4 | · | -2.8 | -2.7 | -3.7 | · | -4.8 | -4.1 | -9.1 | · | -16.2 | -50.0 | 43.7 | · | · | |
| P/S | 1.7 | 1.6 | · | 2.2 | 1.9 | 3.0 | · | 4.7 | 3.8 | 8.2 | · | 8.2 | 10.6 | 9.5 | · | · | |
| P/B | -4.6 | -4.9 | · | -23.4 | -10.9 | -47.1 | · | 23.0 | 8.6 | 12.7 | · | 5.9 | 6.3 | 4.6 | · | 1.5 | |
| P / Tangible Book | · | · | · | · | · | · | · | 24.2 | 8.8 | 12.9 | · | 6.0 | 6.3 | 4.6 | · | 1.5 | |
| P / Cash Flow | · | -11.3 | · | · | · | -20.9 | · | · | · | -19.8 | · | · | · | -39.0 | · | · | |
| EV / Revenue | 2.2 | 2.0 | · | 2.4 | 2.2 | 3.2 | · | 4.7 | 3.6 | 7.6 | · | · | · | · | · | · | |
| Earnings Yield | -34.6% | -42.2% | · | -35.4% | -37.2% | -26.9% | · | -20.8% | -24.6% | -11.0% | · | -6.2% | -2.0% | 2.3% | · | · |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $72M | $64M | $50M | $34M | · |
| Margen Bruto % | 82.1% | 85.9% | 84.5% | 82.5% | · |
| Margen Operativo % | -59.4% | -88.1% | -85.1% | -79.9% | · |
| Beneficio neto | $-49M | $-62M | $-35M | $-27M | · |
| EPS Diluido | $-1.74 | $-2.39 | $-1.40 | $1.07 | · |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Deuda / Patrimonio | -2.6 | 9.4 | 0.8 | · | · |
| Ratio corriente | 0.6 | 2.8 | 7.9 | 8.2 | · |
| Ratio Rápido | 0.4 | 2.4 | 7.3 | 7.7 | · |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-32M | $-58M | $-39M | $-20M | · |
Propietarios institucionales (13F) 80 declarantes · $25.5M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 23 (-6 vs trimestre anterior) | 24 (+11 vs trimestre anterior) | 25 (-4 vs trimestre anterior) | 21 (+11 vs trimestre anterior) | -82.3M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5 509 065 | 1 333 914 | 21,63% | Acciones |
| VANGUARD GROUP INC | $4 983 797 | 1 444 579 | 19,57% | Acciones |
| BlackRock, Inc. | $2 333 251 | 564 952 | 9,16% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $1 404 076 | 339 822 | 5,51% | Acciones |
| MARSHALL WACE, LLP | $1 397 539 | 338 387 | 5,49% | Acciones |
| AQR CAPITAL MANAGEMENT LLC | $1 325 784 | 321 013 | 5,21% | Acciones |
| MORGAN STANLEY | $827 909 | 200 462 | 3,25% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $753 320 | 182 402 | 2,96% | Acciones |
| NewEdge Advisors, LLC | $615 085 | 148 931 | 2,42% | Acciones |
| MACQUARIE GROUP LTD | $595 395 | 144 164 | 2,34% | Acciones |
| STATE STREET CORP | $532 675 | 128 977 | 2,09% | Acciones |
| Quantinno Capital Management LP | $434 674 | 105 248 | 1,71% | Acciones |
| Divisadero Street Capital Management, LP | $413 000 | 100 000 | 1,62% | Acciones |
| UBS Group AG | $347 056 | 84 033 | 1,36% | Acciones |
| GOLDMAN SACHS GROUP INC | $316 924 | 76 737 | 1,24% | Acciones |
| NORTHERN TRUST CORP | $284 858 | 68 973 | 1,12% | Acciones |
| Qube Research & Technologies Ltd | $263 428 | 63 784 | 1,03% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $250 881 | 60 746 | 0,99% | Acciones |
| XTX Topco Ltd | $236 075 | 57 161 | 0,93% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $222 847 | 53 958 | 0,87% | Acciones |
| BANK OF AMERICA CORP /DE/ | $213 384 | 51 667 | 0,84% | Acciones |
| FMR LLC | $134 287 | 32 515 | 0,53% | Acciones |
| IEQ CAPITAL, LLC | $133 812 | 32 400 | 0,53% | Acciones |
| THOMPSON DAVIS & CO., INC. | $128 402 | 31 090 | 0,50% | Acciones |
| Jain Global LLC | $127 101 | 30 775 | 0,50% | Acciones |
| AMERIPRISE FINANCIAL INC | $119 823 | 29 013 | 0,47% | Acciones |
| Russell Investments Group, Ltd. | $115 863 | 28 054 | 0,45% | Acciones |
| IHT Wealth Management, LLC | $101 599 | 24 600 | 0,40% | Acciones |
| Squarepoint Ops LLC | $95 035 | 23 011 | 0,37% | Acciones |
| R Squared Ltd | $94 506 | 22 883 | 0,37% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92 512 | 22 400 | 0,36% | Opción de compra |
| CITADEL ADVISORS LLC | $87 746 | 21 246 | 0,34% | Acciones |
| Mariner, LLC | $81 090 | 19 634 | 0,32% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $65 254 | 15 800 | 0,26% | Opción de venta |
| CITADEL ADVISORS LLC | $65 254 | 15 800 | 0,26% | Opción de venta |
| Abel Hall, LLC | $65 167 | 15 779 | 0,26% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64 734 | 15 674 | 0,25% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $63 722 | 15 429 | 0,25% | Acciones |
| GABELLI FUNDS LLC | $61 950 | 15 000 | 0,24% | Acciones |
| nVerses Capital, LLC | $56 448 | 13 668 | 0,22% | Acciones |
| Cerity Partners LLC | $53 100 | 12 857 | 0,21% | Acciones |
| China Universal Asset Management Co., Ltd. | $51 625 | 12 500 | 0,20% | Acciones |
| Quadrature Capital Ltd | $48 854 | 11 829 | 0,19% | Acciones |
| MERCER GLOBAL ADVISORS INC /ADV | $48 073 | 11 640 | 0,19% | Acciones |
| Vanguard Global Advisers, LLC | $40 201 | 9 734 | 0,16% | Acciones |
| AlphaQuest LLC | $32 354 | 9 378 | 0,13% | Acciones |
| Arax Advisory Partners | $29 542 | 7 153 | 0,12% | Acciones |
| ROYAL BANK OF CANADA | $29 000 | 7 084 | 0,11% | Acciones |
| RHUMBLINE ADVISERS | $27 302 | 6 611 | 0,11% | Acciones |
| CWM, LLC | $19 632 | 5 306 | 0,08% | Acciones |
Informantes de la empresa 20 insiders · 11 directivos · 11 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Cary Guy Vance | President and CEO | 29 de mayo de 2026 A | 40 771 | 0 | 0 | $0 |
| James Corbett | CEO | 21 de enero de 2025 A | 11 580 | 0 | 0 | $0 |
| David D O'Toole | CFO | 12 de junio de 2026 P | 152 927 | 5 | 0 | $45 994 |
| Sean Ekins | Interim CFO | 6 de junio de 2023 A | 5 000 | 0 | 0 | $0 |
| Michael Holder | Chief Financial Officer | 1 de julio de 2022 A | 46 450 | 0 | 0 | $0 |
| David Mcintyre | Chief Financial Officer | 17 de julio de 2020 P | 893 | 0 | 0 | $0 |
| Kathy M. Mcgee | Chief Operating Officer | 1 de julio de 2022 A | 46 450 | 0 | 0 | $0 |
| Nicole Kelsey | Chief Legal Officer | 18 de febrero de 2026 A | 98 390 | 0 | 0 | $0 |
| Donna Shiroma | General Counsel | 31 de mayo de 2024 A | 45 951 | 0 | 0 | $0 |
| Andrew Quick | Chief Technology Officer | 6 de junio de 2023 A | 46 450 | 0 | 0 | $0 |
| Erin Liberto | Chief Commercial Officer | 1 de julio de 2022 A | 46 450 | 0 | 0 | $0 |
| Joseph Fralin Woody | Consejero | 9 de junio de 2026 P | 107 961 | 9 | 0 | $188 600 |
| Suzanne Crowe | Consejero | 20 de enero de 2026 A | 69 148 | 0 | 0 | $0 |
| Michael E Tarnoff | Consejero | 20 de enero de 2026 A | 48 464 | 0 | 0 | $0 |
| Robert Mcnamara | Consejero | 20 de enero de 2026 A | 108 985 | 0 | 0 | $0 |
| Jeremy Curnock Cook | Consejero | 20 de enero de 2026 A | 62 050 | 0 | 0 | $0 |
| Jan Stern Reed | Consejero | 20 de enero de 2026 A | 73 225 | 0 | 0 | $0 |
| Lou Panaccio | Consejero | 21 de enero de 2025 A | 56 428 | 0 | 0 | $0 |
| Michael S Perry | Consejero | 21 de noviembre de 2022 M | 229 543 | 0 | 0 | $0 |
| Louis Drapeau | Consejero | 22 de diciembre de 2021 A | 4 689 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 3 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
RCEL Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
Precio objetivo a 12 meses
3 analistas · 2026-10-01Objetivo medio $12.00 -5,6%
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| SPRY | $1.16B | -6.7 | -5.5% | -203.3% | -111.8% | · |
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| EIKN | · | · | · | · | · | · |
| GALT | $271M | -8.7 | · | · | 25.0% | · |
| RZLT | $501M | -6.9 | · | · | -67.8% | · |
| KYTX | $568M | -2.6 | · | · | -77.4% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.